莫美替尼治疗骨髓纤维化的长期安全性与生存:3期随机对照试验整合分析
本文整合MOMENTUM、SIMPLIFY-1和SIMPLIFY-2三项3期随机试验数据,分析725例接受莫美替尼治疗的骨髓纤维化患者的长期安全性。中位治疗暴露11.3个月,12%患者持续用药≥5年;最常见非血液学不良事件为腹泻(任何级别27%,≥3级3%),因血小板减少停药者占4%,临床重要不良事件发生率未随时间增加。
要点
- 莫美替尼是首个同时抑制JAK1、JAK2和ACVR1的抑制剂,可改善脾肿大、体质性症状和贫血。
- 725例骨髓纤维化患者接受莫美替尼,中位治疗暴露11.3个月,12%持续用药≥5年。
- 临床重要不良事件(感染、恶性转化、周围神经病变、出血)发生率未随时间增加。
核心结论
- 该整合分析显示莫美替尼在骨髓纤维化中具有一致的安全性特征,未观察到长期或累积毒性。
研究设计与样本
- 整合MOMENTUM、SIMPLIFY-1和SIMPLIFY-2三项3期随机对照试验的长期数据,覆盖初治至经治骨髓纤维化患者,共725例接受莫美替尼治疗。
主要发现
- 中位治疗暴露11.3个月(范围0.1-90.4个月),12%患者持续治疗≥5年。
- 最常见的非血液学治疗中出现的不良事件为腹泻,任何级别27%,≥3级3%。
- 任何级别血小板减少、贫血和中性粒细胞减少分别发生于25%、23%和7%的患者。
- 因血小板减少停用莫美替尼的患者占4%,为最常见的停药原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). This long-term analysis pooled data from 3 randomized phase 3 studies of momelotinib (MOMENTUM, SIMPLIFY-1, and SIMPLIFY-2), representing MF disease from early (JAK inhibitor-naive) to late (JAK inhibitor-experienced) stages. Patients in the control arms (danazol in MOMENTUM, ruxolitinib in SIMPLIFY-1, and best available therapy in SIMPLIFY-2) could cross over to receive momelotinib at the end of the 24-week randomized period, and all patients could continue momelotinib treatment after the completion of these studies via an extended access protocol (XAP). Across these studies, 725 patients with MF received momelotinib; 12% remained on therapy for ≥5 years, with a median treatment exposure of 11.3 months (range, 0.1-90.4 months). The most common nonhematologic treatment-emergent adverse event (AE) occurring in ≥20% of patients was diarrhea (any grade, 27% and grade ≥3, 3%). Any-grade thrombocytopenia, anemia, and neutropenia occurred in 25%, 23%, and 7% of patients, respectively. The most common reason for momelotinib discontinuation was thrombocytopenia (4% discontinuation rate). The incidence of AEs of clinical importance (eg, infections, malignant transformation, peripheral neuropathy, and hemorrhage) did not increase over time. This analysis of one of the largest randomized trial databases for a JAK inhibitor to date in MF demonstrated a consistent safety profile of momelotinib without long-term or cumulative toxicity. These trials were registered at www.clinicaltrials.gov as: MOMENTUM (#NCT04173494), SIMPLIFY-1 (#NCT01969838), SIMPLIFY-2 (#NCT02101268), and XAP (#NCT03441113).
引用
- Verstovsek S, Mesa R, Gupta V, et al. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023. PMID: 37042865. doi:10.1182/bloodadvances.2022009311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。